MG
EDIT icon

Mather Group’s Editas Medicine EDIT Stock Holding History

Mather Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$742 – 1843
2024
Q2 		$742 Buy
+100
New +$564 ﹤0.01% 2028

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mather Group's EDIT Position: Q3 2024 in Review

Mather Group sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 100 shares — an estimated $742 sold.

Mather Group first reported a position in EDIT in Q2 2024 and held it in 1 quarter. The position peaked at $742 in Q2 2024. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Mather Group reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 100 Editas Medicine shares in Q3 2024, an estimated $742.
  • Mather Group first reported a position in Editas Medicine in Q2 2024 and held it in 1 quarter.
  • Mather Group's Editas Medicine position peaked at $742 in Q2 2024.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.